Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.4631
- Book/Share 32.4389
- PB 5.4333
- Debt/Equity 0.6469
- CurrentRatio 1.0059
- ROIC 0.1216
- MktCap 424469925000.0
- FreeCF/Share 6.7781
- PFCF 25.887
- PE 18.815
- Debt/Assets 0.2625
- DivYield 0.0285
- ROE 0.3039
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
Published: August 17, 2025 by: The Motley Fool
Sentiment: Negative
Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar competition that erodes their market share.
Read More
Why Is Johnson & Johnson (JNJ) Up 7.2% Since Last Earnings Report?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Back To Basics: Why I Favor Amgen Over Johnson & Johnson
Published: August 14, 2025 by: Seeking Alpha
Sentiment: Positive
Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absorb drug pricing pressure. Both companies have robust profitability and R&D pipelines, but AMGN's growth record and PEGY ratio make it more appealing under current conditions.
Read More
J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson's Q2 MedTech sales beat estimates, fueled by cardiovascular gains, surgical vision growth and new product momentum.
Read More
3 Big Dividend Plays With Strong Earnings to Back Them
Published: August 11, 2025 by: MarketBeat
Sentiment: Positive
Long-term dividend plays tend to be more stable than many other stocks—after all, this stability is why they are able to provide consistent dividends in the first place. Traditional dividend stocks are large, well-established companies that are unlikely to experience significant volatility apart from trends affecting the broader market.
Read More
Worried About a Fading Rally? Consider These 3 Dividend Stocks
Published: August 11, 2025 by: MarketBeat
Sentiment: Negative
Investors have checked plenty of boxes off their 2021 market bingo cards lately: a V-shaped recovery in the S&P 500 after a quick bear market, a wild cryptocurrency rally, and beaten-down meme stocks generating short squeezes.
Read More
Bet on JNJ & Hold on to Apple to Grow Your Retirement Fund Stress-Free
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ offers resilience and income, while Apple fuels long-term growth???ideal picks for a stress-free retirement portfolio.
Read More
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.
Read More
4 Very Safe Dividend Stocks on Goldman Sachs' August Conviction Buy List
Published: August 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest U.S.
Read More
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
Read More
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Published: August 01, 2025 by: Benzinga
Sentiment: Positive
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Read More
5 Dogs of the Dow Are Crushing the S&P 500 and Nasdaq in 2025
Published: July 28, 2025 by: 24/7 Wall Street
Sentiment: Neutral
The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.
Read More
US FDA says J&J's Ethicon issues correction related to surgical stapler
Published: July 25, 2025 by: Reuters
Sentiment: Negative
The U.S. drug regulator said on Friday Ethicon Endo-Surgery, a unit of Johnson & Johnson , issued a correction for certain lots of a part related to its surgical stapler and classified the action as "most serious".
Read More
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.
Read More
Johnson & Johnson Stock Could Be Waking Up
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech segments show promising pipeline developments, with MedTech's growth and robotics ambitions offering future upside. Despite a dip in free cash flow, J&J's dividend remains attractive, with a solid 3.18% yield and a 62-year growth streak, supporting shareholder returns.
Read More
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Read More
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Read More
Best Dividend Kings: July 2025
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.
Read More
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Insider report: These stocks had the biggest sales by executives in the past week
Published: July 21, 2025 by: CNBC
Sentiment: Negative
Some investors follow company insiders on the notion that they would know better than anyone when it's the right time to buy or sell shares. CNBC rounded up some of the biggest sales over the last week.
Read More
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Read More
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
Read More
Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies , including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sites Submission underscores potential to shift the treatment paradigm for moderate-to-severe plaque psoriasis patients with the standout combination of complete skin clearance, a favorable safety profile, and simplicity of a once daily pill SPRING HOUSE, Pa. , July 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a New Drug Application …
Read More
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
Read More
Want Steady Income? 3 Top Dividend Stocks for July 2025
Published: July 17, 2025 by: MarketBeat
Sentiment: Positive
Earnings season is synonymous with market volatility. Growth-oriented investors may love trading the ups and downs, but more risk-averse investors may look for ways to generate solid returns balanced by steady cash flow.
Read More
Johnson & Johnson: The Worst Is Baked In
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Neutral
J&J's diversified business, robust pipeline, and strong free cash flow provide stability despite ongoing legal overhang from talcum powder claims. Legal risks remain a near-term headwind, but I believe any settlement will be manageable for J&J's financial strength and present a buying opportunity. J&J's 63-year dividend growth streak, solid payout ratio, and AAA credit rating make it an attractive choice for long-term, income-focused investors.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100